Ascendis Pharma (ASND) Tops Q1 EPS by 31c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of (EUR0.06), EUR0.31 better than the analyst estimate of (EUR0.37). Revenue for the quarter came in at EUR2.1 million versus the consensus estimate of EUR2.24 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• RUM Group to raise Northern Data stake to ~98% via share purchase
• Oracle raises full year profit guidance, stock rises after hours